A 48-year-old man developed episodic non pitting edema and eosinophilia. Symptoms were alleviated promptly when treated with prednisolone. However, major basic protein (MBP), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin (EDN)levels in the serum as well as the total numberof eosinophils remained high. During periods of attack serum levels of interleukin-5 (IL-5) were elevated, but the levels were lowered following treatment, suggesting that IL-5 is involved in periodic angioedema with eosinophilia. (Internal Medicine 34: 108-111, 1995) 
Introduction
Hypereosinophilic syndrome(HES)is a rare condition characterized by excessive numbers of circulating eosinophils with altered morphology and density (1) . HES has been reported in patients covering a wide range of ages from 5 to 80 years. Untreated patients have a poor prognosis (2) . Some variant forms of HESwith angioedema have been reported to show a milder, longer term course without interfering with vital organ function (3) (4) . The cause of periodic angioedema with eosinophilia is unknown.Eosinophils play an important role in allergic and parasitic diseases and in other inflammatory disorders, probably through the release of toxic proteins into tissues (5) .
Here, we report a patient with episodic angioedemaand eosinophilia. A pathophysiological study in which the levels of eosinophil granule proteins in the patient's serum were measured. Weexamined the serum levels of interleukin-5 (IL -5) during episodes of the illness and performed neutralization experiments on the sera using monoclonal antibodies against various cytokines.
Case Report
A 48-year-old man was admitted to Shinshu University Hospital in May 1989 with periodic systemic edema, skin tightness of both arms and legs, pruritic eruptions on the chest and neck, and marked eosinophilia. Until October 1988, when systemic edema, eruptions on the chest, neck, armand face, myalgia and pruritus appeared, he had been healthy. He noticed these symptoms recurring approximately every 3 weeks. Symptoms lasted from 7 to 15 days. There was no history of bronchial asthma, food or drug allergy, or any other allergic disorders. The patient had never travelled abroad. On admission in May 1989, during a period of recurrent edema, pruritus and myalgia, we examined leukocyte and eosinophil cell numbers, body weight and urine volume. The total leukocyte count at that time showed 12.1xlO9/l with 60% eosinophils, hemoglobin 16. 1 g/dl and ESR 1 mm/h. No ova or parasites were detected in repeated stool examinations. Other peripheral blood tests were performed with normal or negative results except for IgE (1 ,3 12 IU/ml), RA (rheumatoid arthritis) test, and histamine (28 ng/ml/ normal <5 ng/ml). He had no symptoms of RA. High levels of histamine were found in additional test. Analysis of lymphocytes using flow cytometry (EPICS V: Coulter, Fl) showed a normal T cell count, normal percentages of helper and suppressor T cells, a normal helper/ suppressor T cell ratio and normal B cell count. Microscopically, 60% of the peripheral blood leukocytes were mature eosinophils, 7%of eosinophils showed 3 or more nuclear segments. Eosinophils with somevacuoles, a small numberof specific granules in the cytoplasm which were reduced in size were observed by electron microscopy (data not shown). Hypodenseeosinophils with these characteristics have been previously reported (6 Measurement of major basic protein (MBP), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin (EDN) Peripheral blood specimens before and after treatment, and during some periods of periodic angioedema were drawn, which were left at room temperature for 45 min. Serum was obtained by centrifugation at 350 x g for 10 min at 15°C. MBP (7), ECP and EDN (8) were measured by RIA.
Measurement ofIL-5
Serum specimens from the patient were assayed for IL-5 by immunoenzymetric assay: two monoclonal antibodies, JES 1 -39D10 as the coating antibody, and JES1-5A10 derived with hapten nitroiodophenyl as the detecting antibody, in conjunction with L-cell derived recombinant IL-5 as the standard, were used to measure IL-5. This assay has been used to quantify IL-5 in T-cell clone supernatants (9) in addition to mitogenactivated peripheral blood mononuclear cell supernatants ( 1 0).
Serum specimens were stored at -20°C.
Eosinophil survival assay Two hundred jllI of purified human eosinophils (2.5x104/ well) in a flat bottom tissue culture plate (Falcon #3072) were incubated with patient' s serum orrhIL-5 ( 100 pg/ml or 0 pg/ml) for 4 days at 37°C, 5%CO2 in a humidified atmosphere. After 4 days, 120 jil of supernatant was removed from each well, and 10 j l l I of fluorescein diacetate (ll) was added to the cell suspension. After 1 5 min at room temperature, 1 0 jil ofpropidium iodide (12) recombinant human interferon-y (rhIFN-y, GenzymeCo. , Boston, USA) and polyclonal antibody against recombinant human tumor necrosis factor alpha (rhTNF-a, GenzymeCo.) were used for neutralization. Serumspecimens from the patient were each reacted with mAbor combinations of mAbfor 1 hour at room temperature. Then the sera ( 10%, v/v) was cultured with freshly isolated eosinophils as previously described ( 1 3). These antibodies inhibited eosinophil survival by the corresponding cytokine in a dose-dependent manner in preliminary studies.
Each 10 jug of anti-IL-5, anti-IL-3, and anti-GM-CSF mAbs completely neutralized rhIL-5 (300 pg), rhIL-3 (200 pg), and rhGM-CSF (20 pg), respectively. Anti-hlFN-ymAb (2 jug) and anti-hTNF-a polyclonal antibody (5 | il) completely neutralized 800 U and 500 U of each cytokine, respectively. Each antibody of cytokine was specific for its respective cytokine.
Statistical analysis
All results are expressed as mean±SED. Significance was analyzed by paired Student's t-test.
Results
The patient was admitted during a period of recurrent edema, pruritus, skin tightness and myalgia. Weexamined leukocyte and eosinophil cell numbers, body weight and urine volume. Figure 2 shows that the patient's sera during some periods contained considerable eosinophil survival activity (70-94%). Eosinophil survival of normal sera was 12.8±5.6% (N=5).
Eosinophil survival at 100 pg/ml (positive control) and 0 pg/ml (negative control) of rhIL-5 was 92% and 7%, respectively. monoclonal antibodies produced significant inhibition of eosinophil survival (P<0.05), however, alone anti-IL-3 mAb and anti-TNF-a had no effect.
MeasurementofIL-5
Weexamined the relationship between eosinophil cell number and the serum levels of IL-5 during various periods of the syndrome. Table 2 shows that serum levels of IL-5 dropped immediately after treatment, but numbers of eosinophils and Eosinophil survival (%) Fig. 2 . Effect of patient's sera on eosinophil survival. The sera were cultured (10%, v/v) with fresh eosinophils for 4 days, then eosinophil survival was examined. Eosinophil survival at 1 00 pg/ml and 0 pg/ml ofrhIL-5 was 92% and 7%, respectively. Horizontal bars represent standard error of the mean. Leukocyte, eosinophil cell count, and serum level ofIL-5 were measured during periods of periodic angioedema. IL-5 was measured by immunoenzymicassay.
leukocytes were not consistently decreased immediately after tre atment.
Discussion
The term hypereosinophilic syndrome (HES) was introduced by Hardy and Anderson in 1968 (14) to describe patients with peripheral blood eosinophilia for which no cause could be found. Chusid et al (15) defined the syndrome more precisely restricting the diagnosis to patients with 1) persistent eosinophilia (>1.5xlO9/l), 2) a lack of evidence for any known cause, and 3) evidence for multi-organ disease. The present patient with eosinophilia and periodic angioedema showed no evidence of parasitic, allergic or other disease which could cause eosinophilia. Periodic angioedema in this patient appeared approximately every 3 weeks and persisted for up to 15
days. The mechanismof periodic angioedema is not clear. The patient gained about 8% of his normal weight. Interestingly, the total cell number of eosinophils increased during an attack regardless of prednisolone treatment. During an attack there was no significant change in hematocrit or RBC.Fromthese data, it can be suggested that the increased number ofeosinophils was not due to hemoconcentration. The levels ofMBP, ECP and EDNin the patient's serum were always high during an attack and remained high even after treatment. The mechanism of this phenomenonis unclear. It is thought that in spite of treatment, specific granules of humaneosinophils contain low molecular weight, highly basic proteins (MBP, ECP and EDN) which are released from a persistently high number of eosinophils in the peripheral blood by degranulation.
In addition, humanMBPcan induce histamine release in vitro from humanbasophils and rat mast cells (16) . In the present patient, serum histamine levels were consistently elevated and many eosinophils infiltrated into the subcutaneous tissue. These data suggest that eosinophils in the skin released granule constituents which may be the pathophysiologic basis for the angioedema.
IL-5 could be detected in the serum as reported previously (17) ; IL-5 enhances eosinophilopoiesis, and survival and morphologic changes of eosinophils.
The levels of IL-5 in the patient' s serum showed periodic increases which dropped after treatment, thus IL-5 increased in the serum in accordance with periodic eosinophilia. Further, a relationship was found between the level of IL-5 and the prednisolone treatment. However, the eosinophil cell numberwas not significantly reduced by the treatment. Possibly the dose of prednisolone was not sufficient or other eosinopoietic factor(s) were involved in the periodic angioedema. Taken collectively, these data suggest that IL-5 is involved in periodic angioedema with eosinophilia.
